IceCure Medical (NASDAQ:ICCM) Given “Buy” Rating at HC Wainwright

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 125.56% from the company’s current price.

Separately, Alliance Global Partners raised their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a “buy” rating in a research report on Wednesday, March 20th.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM traded down $0.02 during trading on Tuesday, reaching $1.33. 389,729 shares of the company traded hands, compared to its average volume of 669,957. The company has a quick ratio of 3.08, a current ratio of 3.66 and a debt-to-equity ratio of 0.03. The firm has a 50 day simple moving average of $1.28 and a 200-day simple moving average of $1.10. IceCure Medical has a 52-week low of $0.52 and a 52-week high of $1.57. The stock has a market capitalization of $60.67 million, a PE ratio of -4.00 and a beta of 0.73.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $1.26 million during the quarter. IceCure Medical had a negative net margin of 453.76% and a negative return on equity of 86.96%. During the same period last year, the firm posted ($0.11) EPS. Equities research analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Trading of IceCure Medical

Several hedge funds have recently bought and sold shares of ICCM. Bank of America Corp DE raised its stake in IceCure Medical by 57.2% during the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after acquiring an additional 20,159 shares during the period. Boothbay Fund Management LLC boosted its holdings in IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after buying an additional 20,000 shares during the period. UBS Group AG increased its stake in IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after buying an additional 26,919 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in IceCure Medical during the second quarter valued at about $78,000. Institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.